Press release
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX),
About this update from Moonlake Immunotherapeutics
[{"type":"text","content":"MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates. The webcast, streamed live from New York, will start at 8:30 AM EST (2:30 PM CET) and is expected to last one hour. A recording will be made available post event. Webcast Access: https://edge.media-server.com/mmc/p/sgz7i4x9 MoonLake's CEO, Jorge Santos da Silva, CSO, Kristian Reich and CFO, Matthias Bodenstedt will share information on key financial and clinical updates: Financial update Details on the up to $500 million non-dilutive financing agreement with Hercules Capital, which strengthens the Company’s financial position and supports the clinical and commercial objectives while preserving shareholder value. Clinical update: Phase 3 VELA Program in Hidradenitis Suppurativa (HS) Following the conclusion of patient recruitment of the VELA program with the Nanobody® sonelokimab in HS, the management team will share details on the baseline characteristics of the trial and its comparability to Phase 2 MIRA and other competitor trials, as well as narrowed guidance with respect to the timing of the primary endpoint read-out. Clinical update: Phase 2 LEDA Study in Palmoplantar Pustulosis (PPP) An earlier-than-expected interim readout of the LEDA study, highlighting the potential of sonelokimab in the evolving PPP market and further derisking the overall development of the asset. Future strategic outlook Views on market opportunities featuring insights from recent data analyses, competitor performance and strategic imperatives for the company. A Q&A session will follow the presentation. Additional details will be available on the Events & Presentations section of the company’s website at www.ir.moonlaketx.com. - Ends - About MoonLake Immunotherapeutics MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients....